The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 26, 2017

Filed:

May. 10, 2016
Applicant:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Inventors:

Kwame W. Nti-Addae, Tewksbury, MA (US);

Michael Waldo, Grafton, MA (US);

Simon Adam O'Neil, Belmont, MA (US);

John Gregg Van Alsten, Framingham, MA (US);

Dainius Macikenas, Cambridge, MA (US);

Praveen Mudunuri, Waltham, MA (US);

Yi Shi, Natick, MA (US);

Mark Willem Ledeboer, Acton, MA (US);

Valdas Jurkauskas, Cambridge, MA (US);

Ales Medek, Winchester, MA (US);

Steven Jones, Hyde Park, MA (US);

Randal Byrn, Wayland, MA (US);

Mohammed Asmal, Newton, MA (US);

Sarah Marie Robertson, Somerville, MA (US);

Wanjung Tsai, Somerville, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 403/04 (2006.01); A61K 31/506 (2006.01); A61K 31/16 (2006.01); A61K 31/351 (2006.01); A61K 31/4965 (2006.01); A61K 45/06 (2006.01); C07C 309/30 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/16 (2013.01); A61K 31/351 (2013.01); A61K 31/4965 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07C 309/30 (2013.01); C07D 403/04 (2013.01);
Abstract

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½HO, Form F of HCl salt of Compound (1).3HO, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.


Find Patent Forward Citations

Loading…